DSGN · Design Therapeutics, Inc.

Design Therapeutics reported its first quarter 2026 financial results, highlighting a net loss of $17.6 million, slightly improved from $17.7 million in the same period last year. Research and development expenses decreased to $14.4 million from $15.4 million, while general and administrative expenses increased to $5.3 million from $5.0 million. The company ended the quarter with $222.8 million in cash and securities, providing a runway into 2029. Operationally, the company continues to dose patients in its RESTORE-FA Phase 1/2 trial for DT-216P2 in Friedreich ataxia, with an update on frataxin levels expected in the second half of 2026. The Phase 2 biomarker trial for DT-168 in Fuchs endothelial corneal dystrophy is ongoing, with data also anticipated in H2 2026. For myotonic dystrophy type-1, the company expects to begin dosing in a Phase 1 MAD trial for DT-818 in the first half of 2026, with results in 2027. Additionally, David Shapiro, M.D., was appointed to the board of directors in March 2026, bringing clinical and regulatory expertise from his role as former CMO at Intercept Pharmaceuticals. The company's GeneTAC platform continues to advance, with preclinical work ongoing in Huntington's disease.